ATE295170T1 - Verwendung von einem antagonist der zentralen kannabinoidrezeptoren zur herstellung von arzneimitteln - Google Patents
Verwendung von einem antagonist der zentralen kannabinoidrezeptoren zur herstellung von arzneimittelnInfo
- Publication number
- ATE295170T1 ATE295170T1 AT00966200T AT00966200T ATE295170T1 AT E295170 T1 ATE295170 T1 AT E295170T1 AT 00966200 T AT00966200 T AT 00966200T AT 00966200 T AT00966200 T AT 00966200T AT E295170 T1 ATE295170 T1 AT E295170T1
- Authority
- AT
- Austria
- Prior art keywords
- antagonist
- production
- medicinal products
- cannabinoid receptors
- central cannabinoid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9912415A FR2799124B1 (fr) | 1999-10-01 | 1999-10-01 | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
PCT/FR2000/002662 WO2001024798A1 (fr) | 1999-10-01 | 2000-09-27 | Utilisation d'un antagoniste des recepteurs aux cannabinoïdes centraux pour la preparation de medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE295170T1 true ATE295170T1 (de) | 2005-05-15 |
Family
ID=9550596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00966200T ATE295170T1 (de) | 1999-10-01 | 2000-09-27 | Verwendung von einem antagonist der zentralen kannabinoidrezeptoren zur herstellung von arzneimitteln |
Country Status (12)
Country | Link |
---|---|
US (1) | US6642258B1 (de) |
EP (1) | EP1221952B1 (de) |
JP (1) | JP2003510361A (de) |
AR (1) | AR025883A1 (de) |
AT (1) | ATE295170T1 (de) |
AU (1) | AU7667300A (de) |
DE (1) | DE60020145T2 (de) |
DK (1) | DK1221952T3 (de) |
ES (1) | ES2240176T3 (de) |
FR (1) | FR2799124B1 (de) |
PT (1) | PT1221952E (de) |
WO (1) | WO2001024798A1 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
JP2007501279A (ja) * | 2003-05-20 | 2007-01-25 | ユニバーシティ・オブ・テネシー・リサーチ・ファウンデイション | カンナビノイド誘導体、その製造方法、および使用 |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
FR2861303A1 (fr) * | 2003-10-24 | 2005-04-29 | Sanofi Synthelabo | Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique |
WO2006060192A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Pyrazole derivatives |
ES2435790T3 (es) | 2004-12-03 | 2013-12-23 | Intervet International B.V. | Piperazinas sustituidas como antagonistas de CB1 |
US9289583B2 (en) | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US9066847B2 (en) * | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
CA2637565A1 (en) | 2006-01-18 | 2007-07-26 | Schering Corporation | Cannibinoid receptor modulators |
WO2008130616A2 (en) * | 2007-04-19 | 2008-10-30 | Schering Corporation | Diaryl morpholines as cb1 modulators |
BRPI0814806A2 (pt) * | 2007-06-28 | 2015-02-03 | Intervet Int Bv | Pirazinas substituídas como antagonistas de cb1 |
JP2010531874A (ja) * | 2007-06-28 | 2010-09-30 | インターベット インターナショナル ベー. フェー. | Cb1アンタゴニストとしての置換ピペラジン |
ES2534433T3 (es) * | 2007-08-07 | 2015-04-22 | Acelrx Pharmaceuticals, Inc. | Composiciones que comprenden sufentanilo y triazolam para sedación y analgesia operatorias utilizando formas farmacéuticas transmucosas orales |
US8945592B2 (en) * | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
US20110091544A1 (en) * | 2009-10-16 | 2011-04-21 | Acelrx Pharmaceuticals, Inc. | Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting |
WO2013068371A1 (en) | 2011-11-08 | 2013-05-16 | Intervet International B.V. | Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2713225B1 (fr) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
DE19706903A1 (de) * | 1997-02-21 | 1998-08-27 | Bayer Ag | Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1 |
FR2783246B1 (fr) * | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
FR2789079B3 (fr) | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
-
1999
- 1999-10-01 FR FR9912415A patent/FR2799124B1/fr not_active Expired - Fee Related
-
2000
- 2000-09-27 WO PCT/FR2000/002662 patent/WO2001024798A1/fr active IP Right Grant
- 2000-09-27 AU AU76673/00A patent/AU7667300A/en not_active Abandoned
- 2000-09-27 AT AT00966200T patent/ATE295170T1/de not_active IP Right Cessation
- 2000-09-27 PT PT00966200T patent/PT1221952E/pt unknown
- 2000-09-27 ES ES00966200T patent/ES2240176T3/es not_active Expired - Lifetime
- 2000-09-27 US US10/088,704 patent/US6642258B1/en not_active Expired - Fee Related
- 2000-09-27 DK DK00966200T patent/DK1221952T3/da active
- 2000-09-27 EP EP00966200A patent/EP1221952B1/de not_active Expired - Lifetime
- 2000-09-27 DE DE60020145T patent/DE60020145T2/de not_active Expired - Lifetime
- 2000-09-27 JP JP2001527797A patent/JP2003510361A/ja not_active Withdrawn
- 2000-09-28 AR ARP000105103A patent/AR025883A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
ES2240176T3 (es) | 2005-10-16 |
PT1221952E (pt) | 2005-08-31 |
AU7667300A (en) | 2001-05-10 |
AR025883A1 (es) | 2002-12-18 |
EP1221952A1 (de) | 2002-07-17 |
FR2799124B1 (fr) | 2004-08-13 |
JP2003510361A (ja) | 2003-03-18 |
EP1221952B1 (de) | 2005-05-11 |
DK1221952T3 (da) | 2005-08-29 |
US6642258B1 (en) | 2003-11-04 |
FR2799124A1 (fr) | 2001-04-06 |
WO2001024798A1 (fr) | 2001-04-12 |
DE60020145D1 (de) | 2005-06-16 |
DE60020145T2 (de) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE295170T1 (de) | Verwendung von einem antagonist der zentralen kannabinoidrezeptoren zur herstellung von arzneimitteln | |
DE69837473D1 (de) | Verwendung von antagonisten der zentralen kannabinoidrezeptoren zur regulierung von suchterscheinungen | |
DE60017336D1 (de) | Zusammensetzung zur Herstellung von Harzen | |
DE69724142D1 (de) | Sulfonamid-derivate, verfahren zur ihrer herstellung und ihre verwendung als arzneimittel | |
DE69937077D1 (de) | Zwischenprodukte für die Herstellung von Imidazo-Pyridin-Derivate | |
DE60035029D1 (de) | Verfahren zur herstellung von furfural | |
DE69913047D1 (de) | Verfahren zur Herstellung von Benzamid-Derivaten | |
DE60227718D1 (de) | Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen | |
DE69809828D1 (de) | Verfahren zur Herstellung von Nudeln | |
DE50007165D1 (de) | Verfahren zur kontinuierlichen Herstellung hochviskoser füllstoffhaltiger Siliconmassen | |
ATE212034T1 (de) | Derivate von 5-0-desosaminyl-6-0-methyl erythronolid a, ihre verfahren zur herstellung und verwendung zur herstellung von arzneimitteln | |
DE59707046D1 (de) | Kontinuierliches Verfahren zur Herstellung von 4-Aminopiperidinen | |
ATE359285T1 (de) | Verwendung von scopinester derivaten zur herstellung von arzneimitteln | |
DE60024960D1 (de) | Kontinuierliches Verfahren zur Herstellung von Siliconharzen | |
ATE301645T1 (de) | Polycyclische thiazolidin-2-yliden amine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
ID30484A (id) | Turunan 4-heterosikliksulfonamidil 6 metoksi 5 (2 metoksi fenoksi) 2 piridil-pirimidin, pembuatannya dan penggunaan sebagai antagonis reseptor endotelin | |
DE60033877D1 (de) | Verfahren zur Herstellung von Dimethylsulfoxid | |
DE69818698D1 (de) | Inhibitoren von metalloproteinasen, ihre therapeutische verwendung und verfahren zur herstellung der grundstoffe für ihre synthese | |
ATA218299A (de) | Verfahren zur herstellung von oxindolen | |
ATE295175T1 (de) | Verwendung von unverseifbaren pflanzlichen ölen für die herstellung pharmazeutischer präparate | |
DE60214469D1 (de) | Verfahren zur Herstellung von Zirkoniapulver | |
DE60019606D1 (de) | Verfahren zur herstellung von substituierten pyrimidinen | |
DE60002870D1 (de) | Epoxybeschichtete mehrschichtstrukturen für die verwendung in der herstellung von sicherheitsdokumenten | |
DE69916332D1 (de) | Verfahren zur herstellung von etheraminalkoxylaten | |
DE50212938D1 (de) | Derivate von c2-substituierten indan-1-ol-systemen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1221952 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |